A phase II study of the oral factor Xa inhibitor LY517717 for the prevention of venous thromboembolism after hip or knee replacement

Giancarlo Agnelli; Sylvia Haas; Jeffrey S. Ginsberg; K Krueger; Alex Dmitrienko; John T. Brandt

doi:10.1111/j.1538-7836.2007.02436.x

Related publications

Article2003

Direct thrombin inhibitor melagatran followed by oral ximelagatran in comparison with enoxaparin for prevention of venous thromboembolism after total hip or knee replacement

Giancarlo Agnelli, Alexander T. Cohen, Ola E. Dahl, Patrick Mouret, Nadia Rosencher, Christina Eskilson, I Nylander, Lars Frison, Mats ögren, Bengt I. Eriksson

Article2012

New Oral Anticoagulants for Venous Thromboembolism: Focus on Factor Xa and Thrombin Inhibitors

Cecilia Becattini, Alessandra Lignani, Giancarlo Agnelli

Article2025

Factor XI inhibitors for the prevention and treatment of venous and arterial thromboembolism

Davide Capodanno, John H. Alexander, Maria Cecilia Bahit, John W. Eikelboom, C. Michael Gibson, Shaun G. Goodman, Vijay Kunadian, Professor Gregory Lip, Renato D. Lópes, Roxana Mehran, Shamir R Mehta, Manesh R. Patel, Jonathan P. Piccini, Sunil V. Rao, Christian T. Ruff, Philippe Gabríel Steg, Jeffrey I. Weitz, Dominick J. Angiolillo

Article2014

Aspirin for the Prevention of Recurrent Venous Thromboembolism

John Simes, Cecilia Becattini, Giancarlo Agnelli, John W. Eikelboom, Adrienne Kirby, Rebecca Mister, Paolo Prandoni, Timothy Brighton

Chapter in a book2004

Prospects for the prevention and treatment of venous thromboembolism

Giancarlo Agnelli, Cecilia Becattini